Mesa Laboratories, Inc. (NASDAQ: MLAB) Stock Competitors & Peer Comparison

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas SIRO's P/E ratio is 31.88. In terms of profitability, MLAB's ROE is +0.04%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, MLAB is more volatile compared to SIRO. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check SIRO's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas HIMS's P/E ratio is -315.90. In terms of profitability, MLAB's ROE is +0.04%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, MLAB is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check HIMS's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas MMED's P/E ratio is -25.29. In terms of profitability, MLAB's ROE is +0.04%, compared to MMED's ROE of -0.14%. Regarding short-term risk, MLAB is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check MMED's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while OMCL trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas OMCL's P/E ratio is 19.27. In terms of profitability, MLAB's ROE is +0.04%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, MLAB is less volatile compared to OMCL. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check OMCL's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas DRTS's P/E ratio is -19.61. In terms of profitability, MLAB's ROE is +0.04%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, MLAB is less volatile compared to DRTS. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check DRTS's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas LAB's P/E ratio is -11.43. In terms of profitability, MLAB's ROE is +0.04%, compared to LAB's ROE of -0.18%. Regarding short-term risk, MLAB is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check LAB's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, STXS has a market cap of 139M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while STXS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas STXS's P/E ratio is -8.35. In terms of profitability, MLAB's ROE is +0.04%, compared to STXS's ROE of -1.53%. Regarding short-term risk, MLAB is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check STXS's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas FONR's P/E ratio is 19.09. In terms of profitability, MLAB's ROE is +0.04%, compared to FONR's ROE of +0.04%. Regarding short-term risk, MLAB is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check FONR's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas LNSR's P/E ratio is 6.16. In terms of profitability, MLAB's ROE is +0.04%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, MLAB is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check LNSR's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas KDLY's P/E ratio is -15.48. In terms of profitability, MLAB's ROE is +0.04%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, MLAB is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check KDLY's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas NEUE's P/E ratio is -0.38. In terms of profitability, MLAB's ROE is +0.04%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, MLAB is more volatile compared to NEUE. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check NEUE's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas SNWV's P/E ratio is 17.82. In terms of profitability, MLAB's ROE is +0.04%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, MLAB is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check SNWV's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while EKSO trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas EKSO's P/E ratio is -3.11. In terms of profitability, MLAB's ROE is +0.04%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, MLAB is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check EKSO's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas BEAT's P/E ratio is -0.94. In terms of profitability, MLAB's ROE is +0.04%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, MLAB is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check BEAT's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas STSSW's P/E ratio is -0.03. In terms of profitability, MLAB's ROE is +0.04%, compared to STSSW's ROE of N/A. Regarding short-term risk, MLAB is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check STSSW's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas SPAN's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, MLAB is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check SPAN's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, MLAB's ROE is +0.04%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, MLAB is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check EXAC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas ABCO's P/E ratio is 0.52. In terms of profitability, MLAB's ROE is +0.04%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, MLAB is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check ABCO's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas SCAI's P/E ratio is 63.45. In terms of profitability, MLAB's ROE is +0.04%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, MLAB is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check SCAI's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, LDR has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas LDR's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to LDR's ROE of +1.17%. Regarding short-term risk, MLAB is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check LDR's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas MZOR's P/E ratio is -70.18. In terms of profitability, MLAB's ROE is +0.04%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, MLAB is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check MZOR's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas MEDC's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to MEDC's ROE of N/A. Regarding short-term risk, MLAB is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check MEDC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, STJ has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas STJ's P/E ratio is 34.69. In terms of profitability, MLAB's ROE is +0.04%, compared to STJ's ROE of +0.21%. Regarding short-term risk, MLAB is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check STJ's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas LPNT's P/E ratio is 67.44. In terms of profitability, MLAB's ROE is +0.04%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, MLAB is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check LPNT's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas CYNO's P/E ratio is 105.35. In terms of profitability, MLAB's ROE is +0.04%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, MLAB is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check CYNO's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, PMC has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas PMC's P/E ratio is 47.95. In terms of profitability, MLAB's ROE is +0.04%, compared to PMC's ROE of +0.04%. Regarding short-term risk, MLAB is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check PMC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas ABAX's P/E ratio is 70.62. In terms of profitability, MLAB's ROE is +0.04%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, MLAB is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check ABAX's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas EVHC's P/E ratio is -3.20. In terms of profitability, MLAB's ROE is +0.04%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, MLAB is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check EVHC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, COTV has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas COTV's P/E ratio is 26.51. In terms of profitability, MLAB's ROE is +0.04%, compared to COTV's ROE of +0.14%. Regarding short-term risk, MLAB is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check COTV's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas AMSG's P/E ratio is N/A. In terms of profitability, MLAB's ROE is +0.04%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, MLAB is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for MLAB.Check AMSG's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas SPNC's P/E ratio is -24.03. In terms of profitability, MLAB's ROE is +0.04%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, MLAB is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check SPNC's competition here

Mesa Laboratories, Inc. (NASDAQ: MLAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MLAB stands at 574.4M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, MLAB is priced at $102.65 on the NASDAQ, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MLAB currently has a P/E ratio of 10.36, whereas DSCI's P/E ratio is -0.02. In terms of profitability, MLAB's ROE is +0.04%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, MLAB is more volatile compared to DSCI. This indicates higher risk in terms of short-term price fluctuations for MLAB.Check DSCI's competition here